<DOC>
	<DOCNO>NCT01943630</DOCNO>
	<brief_summary>The purpose double blind study determine whether topical 15 % AS101 gel effective safe compare vehicle treatment external genital wart woman .</brief_summary>
	<brief_title>Safety Efficacy Double Blind Vehicle Controlled Study 15 % AS101 Gel Treat External Genital Warts</brief_title>
	<detailed_description>Females external genital wart meet eligibility criterion randomly allocate blind manner 1:1 ratio one 2 follow study arm : ( 1 ) AS101 15 % gel ( 2 ) Vehicle . The patient apply study drug home daily ( overnight ) complete clearance external genital wart 14 week ( 98 day ) . During therapy patient return clinic every 2 week plus/minus 3 day treatment visit clinical assessment treat area . At week 6 treatment investigator evaluate treat area patient . If investigator determines change disease spread area lesion number compare Day 1 , study therapy discontinue prior 14 week ( 98 day ) treatment patient consider clear . Last observation carry forward ( LOCF ) method use analyze patient . Patients week 6 evaluated investigator change disease spread area lesion number compare Day 1 , continue treatment complete clearance wart maximum 14 week ( 98 day ) . Patients evaluate treatment visit complete clearance stop apply study therapy , continue follow per 4 week 84 day ( 12 week ) safety recurrence evaluation . Patients complete treatment partial clearance patient discontinue reason complete clearance follow 28 day discontinuation disease progression reference therapy recommend . Should significant irritation skin adverse reaction occur treatment period , study therapy may hold 7 consecutive day two separate occasion . Unblinding : Patients reveal nature treatment patient complete study . In case pregnancy relate serious adverse event nature treatment reveal patient prior end study . If investigator determines disease progression total lesion number infect wart area size Day 1 treat area , study therapy discontinue prior 98 day treatment .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Ammonium trichloro ( dioxoethylene-O , O'- ) tellurate</mesh_term>
	<criteria>1 . Women least 18 year age good health ; 2 . Must sign ethic committee approve informed consent form able adhere study visit protocol requirement ; 3 . Women must agree avoid sexual contact gel skin ; 4 . All study participant sexually active must use protection method contraception treatment 60 day completion treatment ; 5 . Patients clinical diagnosis external genital wart , external genitalia include vulva ( labia minora majora ) , inguinal fold , pubic area , perineum , perianal , buttock area ; two distinct external genital wart , wart area treat equal less 10 cm2 . Exclusion criterion : 1 . Participation investigational trial within 30 day prior screen ; 2 . Previous participation trial investigate AS101 indication ; 3 . Topical treatment genital wart within 14 day screen ; 4 . Cutaneous surgery , include cryosurgery laser , genital area within 30 day screen ; 5 . Skin irritation clinical sign symptom associate prior therapy . 6 . Topical systemic immunosuppressive immunomodulatory medication ( include corticosteroid ) within 30 day prior screen , study ; 7 . Current active infection herpes genitalis history herpes genitalis infection within last 30 day prior screen ( patient longterm suppressive antiviral therapy eligible ) ; 8 . Diagnosis highgrade cervical dysplasia ; 9 . Internal anogenital , vaginal , cervical wart urethral meatal wart require treatment ; 10 . Chronic acute skin condition might interfere treatment evaluation study drug effect ; 11 . Screening laboratory test result complete blood count ( CBC ) , chemistry panel urine pregnancy test obtain screening : 1 . Must within site laboratory 's define normal reference range , and/or accord Investigator 's decision ; 2 . Urine pregnancy test female childbearing potential must negative ; 3 . Inadequate renal function : Serum Creatinine &gt; 2.0mg/dL ( &gt; 2.0 ULN ) ; 4 . Inadequate liver function : Serum ( total ) Bilirubin &gt; 2 mg/dl ALT and/or AST great two time upper limit reference range . 12 . Uncontrolled infection acute severe febrile illness ; 13 . Diagnosed uncontrolled cardiovascular , hematological , hepatic , neurological , renal , endocrine , vascular , autoimmune , gastrointestinal abnormality disease ; 14 . Pregnant lactating ; 15 . Known allergy AS101 component investigational formulation ; 16 . Subjects clinically significant medical condition , psychiatric condition laboratory abnormality would , judgment Investigator , interfere subject 's ability participate comply trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HPV condyloma acuminata</keyword>
</DOC>